autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02427776)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02427776 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | ImCyse |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImCyse | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1